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BACKGROUND. This annual report to the nation addresses progress in cancer
prevention and control in the U.S. with a special section on colorectal cancer. This
report is the joint effort of the American Cancer Society, the National Cancer
Institute (NCI), the North American Association of Central Cancer Registries
(NAACCR), and the Centers for Disease Control and Prevention (CDC), including
the National Center for Health Statistics (NCHS).
METHODS. Age-adjusted rates were based on cancer incidence data from the NCI
and NAACCR and underlying cause of death as compiled by NCHS. Joinpoint
analysis was based on NCI Surveillance, Epidemiology, and End Results (SEER)
program incidence rates and NCHS death rates for 1973–1997. The prevalence of
screening examinations for colorectal cancer was obtained from the CDC’s Behav-
ioral Risk Factor Surveillance System and the NCHS’s National Health Interview
Survey.
RESULTS. Between 1990 –1997, overall cancer incidence and death rates declined.
Joinpoint analyses of cancer incidence and death rates confirmed the declines
described in earlier reports. The incidence trends for colorectal cancer have shown
recent steep declines for whites in contrast to a leveling off of the rates for blacks.
State-to-state variations occurred in colorectal cancer screening prevalence as well
as incidence and death rates.
CONCLUSIONS. The continuing declines in overall cancer incidence and death rates
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are encouraging. However, a few of the top ten incidence or mortality cancer sites
continued to increase or remained level. For many cancer sites, whites had lower
incidence and mortality rates than blacks but higher rates than Hispanics, Asian
and Pacific Islanders, and American Indians/Alaska Natives. The variations in
colorectal cancer incidence and death rates by race/ethnicity, gender, age, and
geographic area may be related to differences in risk factors, demographic char-
acteristics, screening, and medical practice. New efforts currently are underway to
increase awareness of screening benefits and treatment for colorectal cancer.
Cancer 2000;88:2398 – 424. © 2000 American Cancer Society.
KEYWORDS: neoplasm, incidence rate, mortality, race, surveillance, colon, rectum,
joinpoint, screening.
On the 25th anniversary of the National Cancer Actin 1996, the American Cancer Society (ACS), the
National Cancer Institute (NCI), and the Centers for
Disease Control and Prevention (CDC), which in-
cludes the National Center for Health Statistics
(NCHS), reported the first sustained decline in cancer
death rates since national recordkeeping was insti-
tuted in the 1930s.1-5 For this third annual report,
these organizations, along with the North American
Association of Central Cancer Registries (NAACCR),
are collaborating to monitor cancer statistics and to
describe progress related to cancer prevention and
control in the U.S.4,6 This report updates and confirms
the continuing declines in cancer incidence and death
rates in the U.S. and provides cancer incidence and
death rates in five populations: whites, blacks, Amer-
ican Indians/Alaska Natives (AI/AN), Asian/Pacific Is-
landers (API), and Hispanics for 1990 –1997. Finally,
this report uses a new statistical methodology, join-
point analysis, to describe long term trends and in-
cludes a special section on the occurrence of colorec-
tal cancer and screening.
MATERIALS AND METHODS
All statistics presented in this report plus additional
data on cancer rates of incidence, mortality, survival,
and screening are available from the following URL:
www.seer.cancer.gov.
Cancer Cases
Information regarding newly diagnosed cancer cases
occurring in the U.S. from 1973 to 1997 is based on
data collected by the NCI’s Surveillance, Epidemiol-
ogy, and End Results (SEER) program.5 Briefly, the
SEER program collects cancer incidence data from 11
population-based registries, including five states
(Connecticut, Hawaii, Iowa, New Mexico, and Utah)
and six standard metropolitan statistical areas (Atlan-
ta, Detroit, Los Angeles, San Francisco-Oakland, San
Jose-Monterey, and Seattle-Puget Sound). In addition,
cancer incidence data for Alaska Natives from Alaska
are included with the rates for AI/ANs for 1990 –1997.
Estimates of rates and trends in cancer incidence rates
for the U.S. frequently are based on SEER data. For the
trend analyses, SEER cancer incidence data for 1973–
1997 are from nine geographic areas covering approx-
imately 10% of U.S. population and data for 1990 –
1997 are from 11 geographic areas covering 14% of the
U.S. population. The race/ethnicity-specific incidence
rates for 1990 –1997 also are based on data covering
14% of the U.S. population.5
For the first time, colorectal cancer data from se-
lected population-based cancer registries participating
in the NAACCR annual call–for-data are included. Colo-
rectal cancer incidence rates for 1993–1997 are from
states selected according to whether they meet the cri-
teria established by the NAACCR for highest quality
pooled data for this time period.7,8 Of the 40 states and
10 SEER registries submitting data, 28 met all the criteria.
Furthermore, 23 of these registries exceeded 95% com-
pleteness for case ascertainment. Approximately 49% of
the U.S. population is included in the NAACCR com-
bined colorectal cancer incidence rate.
All information regarding primary tumor site and
histology for incidence was converted to the second
edition of the International Classification of Diseases for
Oncology (ICDO-2).9 The site groupings included in this
report have been published previously.5
Cancer Deaths
Information regarding cancer deaths in the U.S. is
based on causes of death reported by the certifying
physicians on death certificates filed in state vital sta-
tistics offices. The mortality information is processed
and consolidated into a national database by NCHS
(reference 10 and unpublished data).10 The underlying
cause of death is selected for tabulation following the
procedures specified by the World Health Organiza-
tion in the current Manual of the International Statis-
tical Classification of Diseases, Injuries, and Causes of
Death (ICD). For the period 1950 –1957, the sixth re-
vision (ICD-6) was used11; for 1958 –1967, the seventh
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revision (ICD-7) was used12; for 1973–1978, the eighth
revision (ICDA-8) was used13; and for 1979 –1997 the
ninth revision (ICD-9) was used.14 Although the ma-
jority of long term trends presented in this report were
between 1973–1997, trends in age specific death rates
were examined from 1950 –1997 separately for males
and females. For comparability in rates between
1950 –1997, deaths from cancer of the colon/rectum
included deaths due to cancer of the anus and anal
canal. To ensure comparability between the ICDA-8
and ICD-9 codes, ICDA-8 codes on individual records
were converted to ICD-9 codes by applying a conver-
sion algorithm used by the NCI, and the ICD-9 codes
are categorized according to SEER site groups.5
Cancer Incidence and Death Rates
Resident population estimates for each year from the
U.S. Bureau of the Census (unpublished data) were
used to compute age-adjusted cancer incidence and
death rates; population data for whites were adjusted
slightly for an overcount of whites in Hawaii (unpub-
lished data). Because information regarding Hispanic
origin is collected separately from race, persons cate-
gorized as Hispanic were not mutually exclusive from
whites, blacks, AI/AN, and API.
Rates are expressed as per 100,000 population and
are age-adjusted by the direct method to the 1970 U.S.
standard million population. All rates in this report are
based on at least 20 cases or deaths. Death rates are
prepared by the NCI based on numbers of deaths from
the Vital Statistics System of the NCHS and population
estimates as described earlier. For cancer sites that
pertain only to men or women, rates are based on
gender-specific data. The term “all sites” refers to all
cancer sites combined, not to the sum of the sites in
the tables and figures. Specific abbreviations include
lung to designate lung and bronchus, brain to desig-
nate brain and central nervous system, corpus uteri to
designate corpus uteri and uterus not otherwise spec-
ified (NOS), NHL to designate non-Hodgkin lym-
phoma, and IBD to designate intrahepatic bile duct.
For cancer incidence rates, the denominators are
county level population data for the geographic areas
that participate in SEER and for the states that submitted
data to the NAACCR. Cancer incidence rates for AI/AN
are based on data from Alaska plus all SEER registries.
For cancer death rates, the denominators are
county level population data summed across all of the
counties and states for the total U.S., except for His-
panic data. Cancer death rates for Hispanics include
cancer deaths and populations from all states except
Connecticut, Louisiana, New Hampshire, and Okla-
homa, which are omitted due to the absence of com-
parable data on Hispanic origin for all years. Cancer
death rates for AI/AN include data from all states.
Relative Survival Rates
The SEER relative survival rates include cases diag-
nosed in five states (Connecticut, Hawaii, Iowa, New
Mexico, and Utah) and four metropolitan areas (At-
lanta, Detroit, San Francisco-Oakland, and Seattle).
Survival data were calculated by anatomic subsite of
the colon/rectum and stage of disease at diagnosis,
using the third edition of the American Joint Commis-
sion on Cancer (AJCC) TNM staging classification.15
Annual Percent Change
The annual percent change (APC) is estimated by fit-
ting a regression line to the natural logarithm of the
rates using calendar year as a regressor variable (i.e.,
y 5 m x 1 b in which y 5 ln [rate] and x 5 calendar
year). The estimated APC then is equal to 100 * (em -1).
Testing the hypothesis that the APC is equal to zero is
equivalent to testing the hypothesis that the slope of
the line in the above equation is equal to zero (i.e., that
the rate is not increasing or decreasing). The hypoth-
esis test statistic uses the t distribution of m/SE m in
which SE is the standard error of m and the number of
degrees of freedom is equal to the number of calendar
years minus two.16 The calculation assumes that rates
increase or decrease at a constant rate over time al-
though the validity of this assumption has not been
assessed. Statistical significance is assessed using a
two-sided P value 5 0.05.
Joinpoint Analysis
Sometimes rates did not increase (decrease) the same
amount over the entire time period from 1973–1997
(i.e., one straight line [on a log scale] does not fit the
trend). Instead, for many sites, increases occurred in
the early years followed by declines in more recent
years. Joinpoint analysis is a statistical method that
describes changing trends over successive segments of
time and the amount of increase or decrease within
each.17 Joinpoint analysis chooses the best fitting
point(s), called joinpoint(s), at which the rate of in-
crease or decrease changes significantly. The analysis
begins with an assumption of constant change in the
rate over time (i.e., no joinpoint). Up to three join-
points were tested in the model. Thus, in the final
model each joinpoint denotes a significant change in
trend, and each of those trends is described by an
APC. Significant changes may include changes in di-
rection or changes in the rate of increase (decrease).
The rate of change is tested to determine whether it is
different from zero (i.e., significantly increasing or de-
creasing). Lines are used to represent the predicted
2400 CANCER May 15, 2000 / Volume 88 / Number 10
trend and symbols to represent the observed rates in
the joinpoint analyses. The results of the joinpoint
analyses for the major cancer sites are summarized in
Table 1 for incidence and Table 2 for deaths. The
software to perform joinpoint analyses is available
from the Surveillance Research Program of the NCI on
the Worldwide Web at: http://www-dccps.ims.nci.
nih.gov/SRAB/.
To simplify describing the joinpoint analysis, sta-
tistically significant increases or decreases over a par-
ticular segment of time are described as slight if they
were under 1% per year, steady if they were between
1%– 4%, and sharp if they were $ 4%. If the increase or
decrease was not statistically significant, the trend was
described as level. The term “more rapid” was used to
describe increases (or decreases) that became more
pronounced during the next time period.
Colorectal Cancer Screening (National Health Interview
Survey and Behavioral Risk Factor
Surveillance System)
The prevalence of colorectal cancer screening is
based on data collected through the National Health
Interview Survey (NHIS) 18 and the Behavioral Risk
Factor Surveillance System (BRFSS).19 The NHIS is a
continuing nationwide household survey that col-
lects information from a representative sample of
the U.S. civilian, noninstitutionalized population
age $ 18 years.18 The overall response rates for the
1987 and 1992 NHIS surveys were 95.3% (n 5
122,859) and 95.7% (n 5 128,412), respectively.20
Data from the 1998 NHIS are preliminary estimates
of prevalence published as baseline measures for
Healthy People 2010.21
The BRFSS is an ongoing system of telephone
surveys conducted by state health departments in co-
operation with the CDC, and designed to collect risk
factor information and monitor intervention efforts
over time using a population-based, random-digit di-
aled telephone survey of the non-institutionalized U.S.
population age $ 18 years. Some states employ geo-
graphic stratification to oversample specific racial/
ethnic populations. Thus, all analyses are weighted
according to the sampling design.
In 1997, all 50 states, the District of Columbia, and
Puerto Rico participated in the BRFSS. A total of
52,754 persons age $ 50 years were asked whether
they had ever had a blood stool test (also referred to as
fecal occult blood test [FOBT]) using a home-admin-
istered kit and whether they had ever undergone a
sigmoidoscopy or proctoscopy. If they had ever had
the test, respondents also were asked when the last
test was performed. Responses coded as “Don’t know/
Not sure” or “Refused” were excluded from the anal-
ysis (approximately 3%). State-level data were
weighted to the age, gender, and racial/ethnic distri-
bution of the state’s adult population using 1990 cen-
sus or intercensal estimates. Proportions, standard er-
rors, and 95% confidence intervals were calculated
using SAS and SUDAAN 22 to adjust for the sampling
strategies. Percentages were suppressed when numer-
ator or denominator counts were , 20. For the U.S.
estimates, data were aggregated for all 50 states and
the District of Columbia. Of note, BRFSS estimates
presented in this report for the total U.S. do not agree
exactly with previously published estimates 23 because
total U.S. in this analysis did not include Puerto Rico.
Aggregated and state-level data (including Puerto
Rico) are presented for the proportion of respondents
who reported undergoing FOBT or sigmoidoscopy/
proctoscopy during the recommended time period
(e.g., during the preceding year for FOBT and during
the preceding 5 years for sigmoidoscopy/proctoscopy)
by gender, race/ethnicity, and age.
RESULTS
All Sites Combined
Joinpoint analyses revealed three trends in overall
cancer incidence rates from 1973–1997 for all sites
combined, both genders, and all races combined:
slightly increasing on average 0.9% per year from
1973–1983 and steadily increasing on average 1.8% per
year from 1983–1992, followed by a steadily decreasing
rate of -1.3% per year from 1992–1997 (Fig. 1) (Table
1). However, the trends varied by gender and race (Fig.
2). The steadily increasing incidence rates in white
men sharply accelerated to an average of 5.2% per year
between 1989 –1992 but dropped sharply, an average
of -5.1% per year, between 1992–1995 followed by a
leveling off through 1997. Similarly, black men expe-
rienced a sharp increase in the cancer incidence rates
between 1989 –1993 followed by a sharp drop of -4.6%
per year after 1993. In contrast, cancer incidence rates
for white and black women steadily increased until
1987 and 1991, respectively, and then leveled off.
The long term trend of the increasing overall can-
cer death rates (i.e., all sites, both genders, and all
races combined) began to slow in the mid-1980s and
then reversed to a decline after 1991 with a more rapid
decline after 1995 (Fig. 1) (Table 2). Cancer death rates
in white men began to decline after 1990 and de-
creased more rapidly after 1994. Among black men,
the rate of increase in cancer death rates began to slow
after 1983 with a downturn in death rates beginning
after 1991. Cancer death rates for women increased
slightly prior to 1990 and then leveled off after 1990 in
white women and declined slightly after 1991 in black
women.
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TABLE 1
Cancer Incidence Ratesa and Trends for 1990 –1997 and Joinpoint Analysesb for 1973–1997 by Site, Gender, and Race
Site
Average annual
ratea (1990–1997)
APC
(1990–1997)
Joinpoint analyses (1973–1997)
Trend 1 Trend 2 Trend 3 Trend 4
Range of
years APC
Range of
years APC
Range of
years APC
Range of
years APC
All sites 398.1 20.8 1973–1983 0.9c 1983–1992 1.8c 1992–1997 21.3c
Male 478.0 21.7c 1973–1989 1.4c 1989–1992 5.2c 1992–1995 24.6c 1995–1997 20.8
White 476.3 22.1c 1973–1989 1.4c 1989–1992 5.2c 1992–1995 25.1c 1995–1997 20.9
Black 597.9 21.0 1973–1981 2.6c 1981–1989 0.8c 1989–1993 5.4c 1993–1997 24.6c
Female 343.5 20.1 1973–1980 0.2 1980–1987 1.7c 1987–1997 0.2
Black 337.4 20.2 1973–1991 1.1c 1991–1997 20.2
White 352.4 20.2 1973–1980 0.3 1980–1987 1.8c 1987–1997 0.1
Lung 55.2 21.6c 1973–1976 4.1c 1976–1982 2.4c 1982–1991 0.9c 1991–1997 21.5c
Male 73.3 22.8c 1973–1981 1.9c 1981–1992 20.5c 1992–1997 23.2c
White 71.9 23.0c 1973–1980 1.9c 1980–1991 20.3 1991–1997 22.9c
Black 111.1 22.4c 1973–1984 2.9c 1984–1997 21.8c
Female 41.6 20.1 1973–1976 9.1c 1976–1983 5.2c 1983–1991 3.1c 1991–1997 0.0
White 43.3 0.2 1973–1976 10.6c 1976–1988 4.7c 1988–1997 0.9c
Black 45.8 21.3 1973–1990 5.0c 1990–1997 21.5
Prostate 149.7 22.1 1973–1988 2.8c 1988–1992 17.5c 1992–1995 210.3c 1995–1997 0.7
White 145.8 23.0 1973–1988 3.0c 1988–1992 17.5c 1992–1995 211.7c 1995–1997 1.0
Black 225.0 0.7 1973–1989 2.2c 1989–1992 21.8c 1992–1997 24.7c
Female breast 109.7 0.4 1973–1980 20.6 1980–1987 3.8c 1987–1997 0.2
White 114.0 0.3 1973–1980 20.5 1980–1987 4.0c 1987–1997 0.1
Black 100.2 0.7c 1973–1979 20.6 1979–1986 3.8c 1986–1997 1.0c
Colon/rectum 43.9 21.7c 1973–1985 0.8c 1985–1997 21.6c
Male 52.9 22.0c 1973–1985 1.2c 1985–1991 21.2c 1991–1995 23.3c 1995–1997 1.8
White 52.7 22.3c 1973–1985 1.1c 1985–1991 21.3c 1991–1995 23.5c 1995–1997 1.5
Black 58.3 21.6 1973–1980 4.4c 1980–1997 0.0
Female 37.1 21.5c 1973–1984 0.5c 1984–1997 21.6c
White 36.6 21.5c 1973–1984 0.5c 1984–1997 21.8c
Black 45.2 21.2 1973–1980 2.8c 1980–1997 20.3
Urinary bladder 16.4 21.0c 1973–1987 0.9c 1987–1997 20.4c
Male 28.4 21.3c 1973–1987 1.1c 1987–1997 20.8c
White 31.0 21.3c 1973–1988 1.2c 1988–1997 21.0c
Black 15.5 21.9 1973–1977 10.3c 1977–1997 20.2
Female 7.4 20.8c 1973–1975 6.6 1975–1997 0.2c
White 7.9 20.7 1973–1997 0.6c
Black 6.0 21.9 1973–1997 0.5
Non-Hodgkin lymphoma 15.5 0.6 1973–1991 3.4c 1991–1997 0.5
Male 19.4 0.5 1973–1991 3.9c 1991–1997 0.4
White 20.1 0.2 1973–1979 2.6c 1979–1990 4.7c 1990–1997 0.0
Black 15.7 2.3 1973–1997 4.3c
Female 12.2 0.7c 1973–1990 2.9c 1990–1997 0.8
White 12.8 0.2 1973–1990 2.9c 1990–1997 0.5
Black 8.5 1.5 1973–1997 3.4c
Melanoma 12.4 2.6c 1973–1981 6.1c 1981–1997 2.8c
Male 15.3 2.9c 1973–1981 6.9c 1981–1997 3.5c
White 17.4 3.0c 1973–1981 7.2c 1981–1997 3.6c
Black 1.1 4.5 1973–1997 2.9
Female 10.2 2.2c 1973–1981 5.6c 1981–1997 2.0c
White 11.9 2.6c 1973–1980 6.7c 1980–1997 2.2c
Black 0.7 20.4 1973–1997 21.1
Uterine corpus, NOS 21.2 0.1 1973–1975 6.9c 1975–1979 26.5c 1979–1988 21.9c 1988–1997 0.5c
White 22.5 20.2 1973–1975 7.6c 1975–1979 26.7c 1979–1988 21.8c 1988–1997 0.4
Black 15.0 1.5 1973–1997 0.0
(continued)
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Trends between 1990 and 1997
The recent trends for various primary sites by race and
gender can be evaluated in a more equitable way by
comparing the APC over a single time period, 1990–
1997. For all cancer sites combined, SEER incidence
rates decreased (-0.8% per year) (Fig. 3) although the
trend did not achieve statistical significance. The U.S.
cancer death rates for all sites combined decreased sig-
nificantly (–0.8%), the same amount as the incidence
rate during 1990–1997 (Fig. 4).
Site
Average annual
ratea (1990–1997)
APC
(1990–1997)
Joinpoint analyses (1973–1997)
Trend 1 Trend 2 Trend 3 Trend 4
Range of
years APC
Range of
years APC
Range of
years APC
Range of
years APC
Oral cavity/pharynx 10.1 21.8c 1973–1981 0.8c 1981–1997 21.1c
Male 15.1 22.1c 1973–1983 0.2 1983–1997 21.3c
White 14.8 22.2c 1973–1983 20.1 1983–1997 21.4c
Black 20.3 22.7 1973–1981 6.2c 1981–1997 21.4c
Female 5.9 21.3c 1973–1981 1.5c 1981–1997 21.1c
White 5.9 21.5c 1973–1981 1.6c 1981–1997 21.0c
Black 6.0 0.5 1973–1997 20.6
Leukemia 10.4 21.5c 1973–1995 0.0 1995–1997 25.3
Male 13.4 21.7c 1973–1989 0.2 1989–1997 21.5c
White 14.0 22.0c 1973–1992 0.1 1992–1997 22.7c
Black 10.8 22.6 1973–1997 20.5
Female 8.0 21.2c 1973–1997 20.2
White 8.3 21.0 1973–1997 20.1
Black 6.8 23.0c 1973–1997 20.7c
Pancreas 8.8 20.8c 1973–1979 21.3c 1979–1983 1.4 1983–1997 20.7c
Male 10.1 21.0c 1973–1997 20.8c
White 9.8 21.1c 1973–1997 21.0c
Black 14.8 20.7 1973–1997 20.4
Female 7.8 20.8c 1973–1985 0.8c 1985–1997 20.6c
White 7.5 20.9c 1973–1984 0.8c 1984–1997 20.6c
Black 12.1 0.7 1973–1997 0.3
Ovary 14.7 21.3c 1973–1980 21.4c 1980–1991 1.5c 1991–1997 21.1
White 15.6 21.3c 1973–1981 21.1c 1981–1991 1.8c 1991–1997 21.2
Black 10.3 21.4 1973–1997 0.2
Stomach 7.6 21.7c 1973–1997 21.6c
Male 11.1 21.7c 1973–1997 21.6c
White 9.6 22.0c 1973–1997 21.9c
Black 17.0 21.9 1973–1997 21.1c
Female 4.9 22.1c 1973–1997 21.8c
White 4.1 23.0c 1973–1997 22.3c
Black 7.6 20.5 1973–1997 21.1c
Brain 5.9 21.5c 1973–1988 1.5c 1988–1997 20.9c
Male 7.0 21.4c 1973–1989 1.3c 1989–1997 20.9
White 7.6 21.4c 1973–1989 1.4c 1989–1997 20.9
Black 4.4 0.7 1973–1997 0.4
Female 5.0 21.6c 1973–1987 1.7c 1987–1997 21.0c
White 5.4 21.6c 1973–1987 1.9c 1987–1997 21.1c
Black 3.3 22.8 1973–1997 1.2
APC: annual percent change; NOS: not otherwise specified.
a Incidence data are from 11 Surveillance, Epidemiology, and End Results (SEER) registries covering 14 percent of the U.S. population. Rates are per 100,000 persons and are age-adjusted to the 1970 U.S. standard
million population.
b Joinpoint analysis of trends allowed for up to three joinpoints. Incidence data are from 9 Surveillance, Epidemiology, and End Results (SEER) registries covering 10% of U.S. population.
c The annual percent change (APC) is statistically significantly different from 0 (two-sided P , 0.05).
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TABLE 1 (continued)
TABLE 2
U.S. Cancer Death Ratesa and Trends for 1990 –1997 and Joinpoint Analysesb for 1973–1997, by Site, Gender, and Race
Site
Average annual
ratea (1990–1997)
APC
(1990–1997)
Joinpoint analysesb (1973–1997)
Trend 1 Trend 2 Trend 3 Trend 4
Range of
years APC
Range of
years APC
Range of
years APC
Range of
years APC
All sites 169.9 20.8c 1973–1984 0.5c 1984–1991 0.2c 1991–1995 20.6c 1995–1997 21.7c
Male 213.1 21.2c 1973–1980 0.7c 1980–1990 0.2c 1990–1994 20.8c 1994–1997 21.9c
White 207.0 21.2c 1973–1979 0.7c 1979–1990 0.2c 1990–1994 20.7c 1994–1997 21.9c
Black 305.5 21.6c 1973–1983 1.7c 1983–1991 0.6c 1991–1997 21.7c
Female 140.5 20.4c 1973–1990 0.5c 1990–1995 20.2 1995–1997 21.4
White 139.1 20.4c 1973–1990 0.5c 1990–1995 20.1 1995–1997 21.4
Black 167.7 20.4c 1973–1975 21.3 1975–1991 0.9c 1991–1997 20.5c
Lung 49.5 20.5c 1973–1980 2.9c 1980–1990 1.7c 1990–1997 20.5c
Male 71.1 21.7c 1973–1978 2.2c 1978–1984 1.0c 1984–1990 0.3c 1990–1997 21.7c
White 69.5 21.6c 1973–1980 1.8c 1980–1990 0.5c 1990–1997 21.6c
Black 99.5 22.2c 1973–1982 2.9c 1982–1990 1.1c 1990–1997 22.1c
Female 33.4 1.2c 1973–1978 6.8c 1978–1983 5.6c 1983–1990 4.0c 1990–1997 1.3c
White 34.0 1.3c 1973–1976 7.5c 1976–1983 5.9c 1983–1991 3.8c 1991–1997 1.0c
Black 33.0 1.0c 1973–1981 6.6c 1981–1990 4.1c 1990–1997 1.0c
Prostate 25.4 22.2c 1973–1987 0.8c 1987–1991 2.8c 1991–1994 21.2 1994–1997 24.4c
White 23.3 22.4c 1973–1985 0.6c 1985–1991 2.2c 1991–1994 21.1 1994–1997 24.6c
Black 54.1 21.1c 1973–1993 1.9c 1993–1997 22.3c
Female breast 25.6 22.1c 1973–1979 20.2 1979–1990 0.4c 1990–1997 22.2c
White 25.3 22.4c 1973–1979 20.2 1979–1989 0.4c 1989–1995 21.8c 1995–1997 24.1c
Black 31.4 20.2 1973–1991 1.3c 1991–1997 20.3
Colon/rectum 17.6 21.8c 1973–1984 20.6c 1984–1997 21.8c
Male 21.6 22.1c 1973–1985 20.1 1985–1997 21.8c
White 21.3 22.2c 1973–1978 0.4 1978–1986 20.6c 1986–1997 22.0c
Black 27.7 20.7c 1973–1989 1.3c 1989–1997 20.6
Female 14.7 21.7c 1973–1984 21.1c 1984–1997 21.9c
White 14.3 21.8c 1973–1984 21.2c 1984–1997 22.1c
Black 19.9 21.0c 1973–1985 0.5c 1985–1997 20.7c
Urinary bladder 3.2 20.3 1973–1977 20.9c 1977–1987 22.3c 1987–1997 0.0
Male 5.6 20.7c 1973–1976 0.1 1976–1987 22.1c 1987–1997 20.4c
White 5.8 20.5c 1973–1976 0.1 1976–1987 22.1c 1987–1997 20.3c
Black 4.5 22.5c 1973–1997 21.4c
Female 1.7 0.0 1973–1987 21.8c 1987–1997 0.1
White 1.7 0.2 1973–1987 21.8c 1987–1997 0.2
Black 2.3 20.7 1973–1997 21.2c
Non-Hodgkin lymphoma 6.7 1.7c 1973–1976 20.9 1976–1997 2.1c
Male 8.3 1.5c 1973–1976 21.4 1976–1997 2.2c
White 8.6 1.5c 1973–1977 20.3 1977–1997 2.2c
Black 6.2 2.3c 1973–1979 20.7 1979–1997 2.9c
Female 5.4 1.8c 1973–1975 21.5 1975–1997 1.9c
White 5.7 1.9c 1973–1975 21.7 1975–1997 1.9c
Black 3.7 1.6c 1973–1997 2.4c
Melanoma 2.2 0.1 1973–1977 4.1c 1977–1989 1.3c 1989–1997 0.1
Male 3.2 0.4 1973–1987 2.5c 1987–1997 0.6c
White 3.5 0.5c 1973–1987 2.6c 1987–1997 0.7c
Black 0.4 24.0 1973–1997 21.1c
Female 1.5 20.3 1973–1979 3.0c 1979–1997 0.0
White 1.7 20.3 1973–1979 3.1c 1979–1997 0.2
Black 0.4 20.8 1973–1997 0.2
Uterine corpus, NOS 3.3 20.7c 1973–1989 21.7c 1989–1997 20.7c
White 3.1 20.7c 1973–1991 21.7c 1991–1997 20.4
Black 5.8 21.0 1973–1997 21.1c
(continued)
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The recent trends in cancer incidence and death
rates varied not only by gender but also by age at
diagnosis or death. During 1990 –1997, statistically sig-
nificant decreases in incidence rates for all sites com-
bined occurred in men who were ages 25– 44 years and
men age $ 75 years at the time of diagnosis. Incidence
trends in women were less consistent with age. Death
rates for all cancers combined declined for all age
groups of men and for women age , 75 years. The
only significant increases in cancer death rates were
noted for women age $ 75 years.
Among the ten leading cancer incidence sites,
rates decreased between 1990 –1997 for the majority of
sites (Fig. 3). The only significant increases were noted
Site
Average annual
ratea (1990–1997)
APC
(1990–1997)
Joinpoint analysesb (1973–1997)
Trend 1 Trend 2 Trend 3 Trend 4
Range of
years APC
Range of
years APC
Range of
years APC
Range of
years APC
Oral cavity/pharynx 2.7 22.6c 1973–1979 20.2 1979–1997 21.9c
Male 4.2 22.8c 1973–1979 20.6 1979–1997 22.1c
White 3.8 22.6c 1973–1977 21.0 1977–1997 22.3c
Black 8.4 23.8c 1973–1980 3.8c 1980–1993 21.3c 1993–1997 24.8c
Female 1.5 22.3c 1973–1979 0.5 1979–1991 21.4 1991–1997 22.5c
White 1.5 22.3c 1973–1979 0.6 1979–1997 21.7c
Black 2.1 22.5c 1973–1981 1.4 1981–1997 21.4c
Leukemia 6.3 20.4c 1973–1997 20.3c
Male 8.3 20.4 1973–1997 20.3c
White 8.5 20.3 1973–1997 20.3c
Black 7.8 20.7 1973–1997 0.4c
Female 4.8 20.7c 1973–1997 20.3c
White 4.9 20.6c 1973–1997 20.4c
Black 4.6 20.7 1973–1981 1.3c 1981–1997 20.3
Pancreas 8.4 20.4c 1973–1997 20.2c
Male 9.8 20.7c 1973–1997 20.6c
White 9.6 20.5c 1973–1986 20.9c 1986–1997 20.3c
Black 13.8 21.6c 1973–1992 0.4c 1992–1997 22.4c
Female 7.2 20.2 1973–1984 0.6c 1984–1997 0.0
White 7.0 20.1 1973–1983 0.5c 1983–1997 0.1
Black 10.4 20.2 1973–1984 2.0c 1984–1997 0.2
Ovary 7.6 20.9c 1973–1984 21.0c 1984–1991 0.4 1991–1997 21.0c
White 7.9 20.9c 1973–1976 0.5 1976–1980 22.2c 1980–1994 0.0 1994–1997 21.7
Black 6.4 21.0 1973–1997 20.2
Stomach 4.3 22.8c 1973–1977 23.3c 1977–1987 22.4c 1987–1990 20.6 1990–1997 22.8c
Male 6.2 23.1c 1973–1978 23.3c 1978–1991 21.9c 1991–1997 23.1c
White 5.5 23.4c 1973–1978 23.4c 1978–1991 22.1c 1991–1997 23.3c
Black 12.3 22.8c 1973–1997 21.6c
Female 2.9 22.6c 1973–1987 22.8c 1987–1990 20.5 1990–1997 22.5c
White 2.5 23.0c 1973–1987 23.1c 1987–1990 20.8 1990–1997 23.0c
Black 5.4 22.2c 1973–1997 21.5c
Brain 4.2 20.7c 1973–1977 1.2c 1977–1980 6.9c 1980–1991 0.9c 1991–1997 20.6
Male 5.1 20.8c 1973–1977 1.5 1977–1980 7.1c 1980–1991 0.8c 1991–1997 20.8
White 5.4 20.7c 1973–1977 1.4 1977–1980 8.0c 1980–1997 0.5c
Black 3.0 21.3 1973–1986 3.0c 1986–1997 20.8
Female 3.5 20.6 1973–1977 1.1 1977–1980 6.6c 1980–1991 0.9c 1991–1997 20.5
White 3.7 20.6 1973–1977 1.1 1977–1980 7.5 1980–1997 0.6c
Black 2.1 0.1 1973–1975 29.9 1975–1979 9.4c 1979–1997 0.8c
APC: annual percent change; NOS: not otherwise specified.
a Rates are per 100,000 persons and are age-adjusted to the 1970 U.S. standard million population.
b Joinpoint analysis of trends allowed for up to three joinpoints. Death data are from National Center for Health Statistics (NCHS) covering the entire U.S. population.
c The annual percent change is statistically significantly different from 0 (two-sided P , 0.05).
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TABLE 2 (continued)
for NHL among women and melanoma among both
genders. Among men, significant declines were ob-
served for cancers of the lung, colon/rectum, urinary
bladder, and oral cavity/pharynx, and for leukemia
(Fig. 3). Prostate cancer decreased with the decrease
occurring primarily after 1992; however, it was not
significant. For women, overall cancer incidence rates
did not change appreciably between 1990 –1997. Slight
nonsignificant increases were found for cancers of the
breast and corpus uteri and significant increases were
found for NHL and melanoma. Significant declines
were observed for cancer of the colon/rectum, urinary
bladder cancer, leukemia, and of the oral cavity/phar-
ynx. Female lung cancer incidence rates have leveled
off in the SEER areas, but the death rates for the U.S.
have not.
Among the ten leading mortality sites, rates de-
creased between 1990 –1997 for the majority of sites
(Fig. 4). The only significant increases noted were for
female lung cancer and NHL for both genders. For
men, significant decreases were observed in all sites
combined, lung, colon/rectum, prostate, pancreas,
stomach, and brain. For women, significant declines
were noted for all sites combined, colon/rectum,
breast, leukemia, stomach, and ovaries.
The four leading cancer incidence rate sites
were the lung, prostate, female breast, and colon/
rectum, and together they accounted for approxi-
mately 54% of all new diagnoses.24 Examination of
incidence rates for these four sites by race and eth-
nicity revealed that, with the exception of female
breast cancer, blacks had higher incidence rates
than whites, Hispanics, AI/AN, and API (Fig. 5).
These four sites also were the leading four causes for
cancer death for each of the racial/ethnic groups (Fig. 5)
and accounted for . 50% of the cancer deaths in the
U.S.24 Again, blacks had higher overall death rates than
the other racial/ethnic groups.
Lung and Bronchus
Trends in the incidence rates of cancer of the lung and
bronchus differ by gender and race (Table 1). Rates in
white men steadily increased between 1973–1980, lev-
eling off around 1980, and then began to steadily
decrease after 1991. Rates in black men steadily rose
until about 1984 but have since steadily declined. In
contrast, incidence rates for white women continued
to increase sharply between 1973–1976 (averaging
10.6% per year) with a slowing of the increase in rates
between 1976 –1988 to approximately 4.7% per year,
and then slowed again to 0.9% per year after 1988.
After climbing an average of 5.0% per year, incidence
rates for black women appeared to be leveling off
around 1990.
For men, lung cancer ranks as the second highest
cancer site after prostate cancer at a rate of 73.3 per
100,000. It is second highest for each of the racial/
ethnic groups (Fig. 5). However, the rates vary widely,
from a low of 38.0 per 100,000 for Hispanics to 111.1
for black men. The incidence rates for Hispanic, AI/
AN, and API men were all less than half the rate for
black men. For women, lung cancer is the second
highest cancer for white and black women, but third
highest for Hispanics, AI/AN, and API. Similarly, the
rates varied widely by race/ethnicity from a low of 19.4
per 100,000 among Hispanics to a high of 45.8 among
blacks. Lung cancer incidence rates among white
women were similar to those for black women. The
rates were similar among Hispanic, AI/AN, and API
women.
Similar to incidence rates, trends in death rates
FIGURE 1. All cancers, incidence and death rates, for all races, both genders,
with joinpoint analyses for 1973–1997. a Incidence data are from 9 Surveil-
lance, Epidemiology and End Results (SEER) program areas covering 10% of
U.S. population. Death data are from the National Center for Health Statistics
(NCHS) covering the entire U.S. population. Rates are per 100,000 persons and
age-adjusted to the 1970 U.S. standard million population.
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from cancer of the lung and bronchus differed dra-
matically by gender and race. Death rates for men had
increased for decades (data not shown), but the in-
crease slowed for white men around 1980 and for
black men after 1982. Death rates began to drop
steadily for white men and for black men after 1990.
However, death rates from cancers of the lung and
bronchus among women have continued to increase
over time although with progressive slowing of the
rates of increase observed for both white and black
women. Lung cancer is the number one cause of can-
cer death among men and women for all race/ethnic
groups, except Hispanic women.
Prostate
Prostate cancer incidence rates fluctuated dramati-
cally (Table 1). Rates steadily increased for both white
and black men in the 1970s and early 1980s. In white
men, rates escalated rapidly, on average 17.5% per
year from 1988 –1992, dropped markedly (averaging
-11.7% per year) from 1992–1995, and have since lev-
eled off. Similarly, rates for black men accelerated
dramatically (21.8% per year) from 1989 to around
1992 but have since continued to decline sharply (av-
eraging -4.7% per year). Prostate cancer is the number
one cancer site in men for each of the race/ethnic
groups. However, the rates vary . 4-fold, from 49.6
per 100,000 for AI/AN men to 225.0 for black men (Fig.
5).
In addition, death rates from prostate cancer have
varied considerably over time (Table 2). Death rates in
white men increased slowly during the 1970s until the
mid-1980s, climbed more rapidly after 1985, reversed
course to decline after 1991, but started dropping
sharply (averaging -4.6% per year) after 1994. Among
black men, the pattern differed in that death rates
steadily increased until 1993 and since that time have
steadily decreased (averaging -2.3% per year). Prostate
cancer death rates among black men were more than
twice those for the other race/ethnicity groups
(whites, Hispanics, AI/AN, and API) (Fig. 5).
Female Breast
Incidence rates of invasive female breast cancer in
white women steadily increased between 1980–1987 but
have since leveled off (Table 1). Similarly, incidence rates
in black women steadily rose between 1979–1986 fol-
lowed by a slowing of increasing rates since 1986. Among
women, breast cancer is the number one cancer site
regardless of race/ethnicity. The rates are more than
double among whites (114.0 per 100,000) compared with
AI/AN (45.4 per 100,000) (Fig. 5).
In contrast, breast cancer death rates in white
women were level until 1979, increased slightly from 1979–
1989, began to decrease steadily after 1989, and dropped
sharply (averaging -4.1% per year) after 1995 (Table 2). Over
the same time period, death rates for black women
FIGURE 2. All cancers, incidence and
death rates by gender and race, with
joinpoint analyses for 1973–1997. a In-
cidence data are from 9 Surveillance,
Epidemiology, and End Results (SEER)
program areas covering 10% of U.S.
population. Death data are from the Na-
tional Center for Health Statistics (NCHS)
covering the entire U.S. population.
Rates are per 100,000 persons and age-
adjusted to the 1970 U.S. standard mil-
lion population.
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climbed steadily but began to level off after 1991. Except for
Hispanic women, breast cancer is not the number one
cause of cancer death. It ranks second among all cancer
deaths after lung cancer (Fig. 5).
Urinary Bladder
Incidence rates for cancer of the urinary bladder
steadily increased in white men until 1988 and subse-
quently declined steadily (Table 1). Incidence rates in
black men sharply increased (averaging 10.3% per
year) over a short period of time in the mid-1970s,
after which time rates leveled off. Cancer of the uri-
nary bladder is one site in which white men have
much higher incidence rates than black men (31.0 per
100,000 vs. 15.5 per 100,000) (Fig. 5). Incidence rates
are much higher among men than women.
Incidence rates for white women have increased
slightly throughout the study period and remained
approximately level for black women.
Death rates for carcinoma of the urinary bladder
have declined steadily for black men and for black
women throughout the study period (Table 2). In con-
trast death rates for white men remained level and did
not begin to decline until after 1976, with a slowing of
the decline occurring after 1987. Unlike their male or
black counterparts, death rates in white women
steadily declined between 1973 and 1987 and then
leveled off.
Non-Hodgkin Lymphoma
The incidence rate of NHL in white men steadily in-
creased between 1973 and 1979, then sharply in-
creased (averaging 4.7% per year) from 1979 to 1990
with a leveling off of the rates after approximately
1990. The rates for black men and women increased
substantially (on average 4.3% and 3.4% per year, re-
spectively) throughout the study period. White women
had steady increases of NHL with a leveling off of the
rates beginning around 1990.
Death rates from NHL were fairly level but have
steadily increased since the mid-to-late 1970s for
white men, black men, and white women. Death rates
have steadily increased throughout the study period
for black women.
FIGURE 3. Annual percent change (APC) in cancer incidence rates,a top ten
sites by gender, all ages, all races, 1990–1997. a Incidence data are from 11
Surveillance, Epidemiology, and End Results (SEER) program areas covering
14% of U.S. population. Rates are per 100,000 persons and age-adjusted to the
1970 U.S. standard million population. # APC is based on gender-specific rates;
NOS: not otherwise specified. lym: lymphoma. * The APC is statistically signif-
icantly different from zero (2-sided P , 0.05).
FIGURE 4. Annual percent change (APC) in cancer death rates,a top ten sites
by gender, all ages, all races, 1990–1997. a Death data are from National
Center for Health Statistics (NCHS) covering the entire U.S. population. Rates
are per 100,000 persons and age-adjusted to the 1970 U.S. standard million
population. # APC is based on gender specific rates. * The APC is statistically
significantly different from zero (2-sided P , 0.05). lym: lymphoma; ONS: other
nervous system.
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Melanoma of the Skin
Incidence rates for melanoma of the skin steadily in-
creased for white men and for white women throughout
the study period but a slowing in the increasing rates was
observed in approximately 1981 (Table 1). The incidence
rate of melanoma of the skin in blacks is very low com-
pared with whites and has been approximately level for
black men and women throughout the study period.
Death rates from melanoma of the skin increased
for whites throughout the study period but a slowing in
the increasing death rate was observed after 1979 for white
women and after 1987 for white men (Table 2). Death rates
from melanoma of the skin in blacks were quite low but
appeared to decrease in black men and to remain level in
black women throughout the study period.
Corpus Uteri and Uterus, NOS
Rates of newly diagnosed cancer of the corpus and
uterus, NOS in white women fluctuated substantially
during the study period with sharp increases (7.6% per
year) between 1973–1975, and sharp decreases (aver-
aging -6.7% per year) between 1975–1979. Between
1979 –1988, the rates continued to decrease but fell
only –1.8% per year. After 1988, the incidence rates
leveled off for white women (Table 1). In contrast, the
incidence rates for black women have been level
throughout the study period. Death rates from carci-
noma of the corpus and uterus NOS steadily declined
for both black and white women but leveled off after
1991 for white women (Table 2).
Oral Cavity and Pharynx
The incidence rate of cancer of the oral cavity and
pharynx was level in white men until 1983 followed by
a steady decline through 1997 (Table 1). The incidence
rate in white women steadily rose until 1981 followed
by steady decreases throughout the remainder of the
study period. Rates climbed sharply (averaging 6.2%
per year) in black men until 1981 but have since
steadily decreased. Rates remained level throughout
the study period for black women.
Death rates for carcinoma of the oral cavity and
pharynx steadily declined since 1977 for white men
(Table 2). In contrast, rates increased for black men
until 1980 and then began falling with a sharper drop
starting after 1993. Trends for death rates for white
and black women were similar, being approximately
level during the 1970s followed by steady declines
beginning after 1979 for white women and after 1981
for black women.
Leukemias
The incidence rates of leukemia in white men were
level in the 1970s and 1980s but began to decrease
steadily after 1992 (Table 1). Incidence rates in black
men and white women remained approximately level
from 1973–1997 whereas rates decreased slightly
among black women.
From 1973–1997, leukemia death rates for white
men and women dropped slightly. Death rates in
black men increased slightly throughout the study
period while the rates in black women increased
steadily until 1981, at which time the rates leveled off
(Table 2).
Pancreas
The incidence of pancreatic cancer decreased for
white men and remained level for black men and
women over the study period. For white women, the
rates increased slightly until 1984 and then declined
on average -0.6% per year.
Death rates from pancreatic cancer decreased for
white men throughout the study period, but at a
slower rate since approximately 1986. Death rates in
black men did not begin to drop steadily until after
1992. Death rates in white and black women increased
until 1983 and 1984, respectively, after which time the
rates leveled off.
Ovary
The incidence rates of ovarian cancer have remained
level for black women and vacillated for white women
between a steady decrease between 1973–1981 and a
steady increase between 1981–1991 followed by a non-
significant decline (Table 1). Trends in death rates
from ovarian cancer in black women generally have
remained level between 1973–1997 and fluctuated for
white women, with a significant decline occurring be-
tween approximately 1976 –1980 and level rates until
1994, at which time rates began to decrease slightly
(Table 2).
Stomach
The incidence rates of stomach cancer steadily de-
creased for whites and blacks and men and women
throughout the study period. During the same time
period, death rates from stomach cancer also de-
clined for both genders as well as for blacks and
whites.
Brain
The incidence of brain cancer increased steadily be-
fore 1990 among white men and then remained ap-
proximately level (Table 1). For white women, the
incidence rates increased steadily between 1973–1987
and then decreased approximately –1.1% per year. The
rates for blacks remained fairly level during the study
period.
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Death rates from brain cancer were level in the
early-to-mid-1970s for white men, white women, and
black women. Substantial increases occurred in the
late 1970s, followed by a substantial slowing of the
increase in rates around 1980 (Table 2). Death rates in
black men steadily increased until 1986 and then lev-
eled off.
Liver
Liver cancer was not in the top cancer sites overall, but
death rates were highest among API, as shown in
Figure 5.
Special Section on the Colon and Rectum
Colorectal cancer incidence
Overall, colon/rectum is the third highest cancer site
for U.S. men (after the prostate and lung). For U.S.
women, colorectal cancer ranks second to breast can-
cer for Hispanic, AI/AN, and API and ranks third after
breast cancer and lung cancer for white and black
women. Regardless of race, colorectal cancer inci-
dence rates are higher in men than women. For all
races combined, the colorectal cancer incidence rate
is over 40% higher among males than females. The
ACS estimates that there will be 93,800 new diagnoses
FIGURE 5. Cancer incidence and
death ratesa by site and race/ethnicity,
1990–1997. a Incidence data are from
11 Surveillance, Epidemiology, and End
Result (SEER) program areas covering
14% of U.S. population. Death data are
from the National Center for Health Sta-
tistics (NCHS) covering the entire U.S.
population. Rates are per 100,000 per-
sons and age-adjusted to the 1970 U.S.
standard million population. b Hispanic is
not mutually exclusive from whites,
blacks, American Indians/Alaska Na-
tives, and Asian/Pacific Islanders.
# Rates are based on gender specific
data; NOS: not otherwise specified; ONS:
other nervous system; IBD: intrahepatic
bile duct.
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of colon cancer and 36,400 new diagnoses of rectal
cancer in the year 2000 in the U.S.24
The joinpoint analysis showed that the incidence
rates of colorectal cancer increased until 1985 and
then began decreasing steadily, an average of –1.6%
per year (Fig. 6) (Table 1). In white men, colorectal
cancer incidence rates began decreasing after 1985
and then declined more rapidly between 1991–1995
but leveled off subsequently (Table 1) (Fig. 7). Rates in
black men increased sharply from 1973–1980 (averag-
ing 4.4% per year) but have been level since that time.
Between 1973 and 1990 the joinpoint analysis esti-
mated lower rates for black men than for white men
(Fig. 7). However, after 1990 the rates for white men
dropped below those for blacks. Rates for Hispanic
and AI/AN men were lower than those for white,
black, or API men (Fig. 8). For white women, the
incidence rates of colorectal cancer increased slightly
until around 1984 but have steadily decreased since
then (Table 1). After steadily rising, the colorectal can-
cer incidence rates in black women have been approx-
imately level since 1980. Black women had higher
incidence rates than whites and incidence rates
for API, Hispanic, and AI/AN women were similar
(Fig. 8).
Colorectal cancer incidence rates are low for
young Americans ages 20 –39 years and high for older
Americans age $ 85 years. For patients age $ 50 years,
FIGURE 5. (continued)
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rates are higher for men than women. For individuals
age , 50 years the rates are similar. Incidence rates for
men declined later than for women. Furthermore, in-
cidence rates declined earlier for the younger age
groups than for the older groups for both genders
based on trends between 1974 –1997.
Colorectal cancer mortality
Similar to incidence, deaths from colorectal cancer
rank third after cancers of the lung and prostate for
men and third after cancers of the lung and breast for
women. The ACS estimates 47,700 deaths from colon
cancer and 8,600 deaths from rectal cancer will occur
in the year 2000.24
Colorectal cancer death rates in white men were
level between 1973–1978 and then began to decline
-0.6% per year from 1978 –1986, followed by a more
rapid decrease of -2.0% per year beginning around
1986 (Table 2) (Fig. 7). In contrast, death rates in
black men rose steadily before 1989 and then lev-
eled off. Before the early 1980s, colorectal cancer
death rates for black men were lower than those
for white men. With the rates for black men leveling
off and the rates for white men declining, the rates
for white men became much lower than those for
black men. Colorectal cancer death rates in white
women declined between 1973–1997 with a more
rapid decline after 1984, averaging -2.1% per year (Ta-
ble 2). In contrast, the death rates for black women did
not start to decline until 1985, and the amount of decline
was much less than that for white women (Fig. 7).
Colorectal cancer death rates for Hispanics, AI/AN,
and API were lower than those for whites or blacks
(Fig. 8).
Long term (1950–1997) trends in colorectal
cancer mortality
For women, colorectal cancer mortality rates have been
declining since 1950. In contrast, the rates for men were
fairly level and then began declining in the 1980s. For
ages 20–39 years and 40–49 years, colorectal cancer
mortality rates declined for men since 1950. For women,
the mortality rates for all age groups , 60 years have
declined since 1950. For the other age groups, the de-
cline in the rates for women started earlier than those for
men in comparable age groups.
Incidence rates by anatomic subsite of the colon/rectum
Incidence rates for the transverse colon were similar
for blacks and whites and males and females (Fig. 9).
In contrast, differences by gender and race (white vs.
black) were noted for the descending colon and
splenic flexure, with black men having the highest
rates and white women the lowest. All anatomic sub-
sites showed declines in the incidence rates except the
right side of the colon (cecum, appendix, ascending
colon, and hepatic flexure) (Fig. 9).
State-specific colorectal cancer occurrence
In the most recent 5-year period (1993–1997) colorec-
tal cancer incidence rates ranged from 32.4 new cases
per 100,000 to 51.9 cases per 100,000 for both genders
and all races combined among the 28 selected U.S.
states and areas (Table 3). The race-specific ranges for
FIGURE 5. (continued)
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both genders were similar among whites and blacks,
albeit the range of rates was a little higher among
blacks. Greater male/female differences were found in
each area than black/white differences. Composite
rates from the SEER program and NAACCR were sim-
ilar with slightly higher estimates generated for all
races and for whites by NAACCR and for blacks by
SEER.
For 1993–1997, the state-specific death rates for
colorectal cancer ranged from 12.3 per 100,000 to 20.0
per 100,000 for both genders and all races combined.
Similar to incidence, the larger differences were be-
tween men and women than between black and white
persons within the same state (Table 4).
Survival
The overall 5-year relative survival rate for colorectal
cancer was 61%. Survival rates varied by AJCC TNM
stage as expected from a high of 96% for Stage I to 87%
for Stage II, 55% for Stage III, and 5% for Stage IV
disease. The 5-year relative survival rates did not vary by
anatomic subsite of the colon/rectum as significantly
and ranged from 57% for the appendix or splenic flexure
to 67% for the sigmoid colon. Survival rates were similar
(between 59–61%) for the cecum, hepatic flexure, trans-
verse colon, and rectosigmoid but were higher for the
ascending colon (63%), descending colon (64%), and
sigmoid colon (67%). An interrelation exists between
stage and segment; the appendix had both the lowest
survival rate and the lowest percentage of Stage I cases
(6%) whereas the sigmoid colon had the highest percent-
age of Stage I cases (22%). The relative survival rate for
large intestine, NOS in which the segment was not spec-
ified was low (28%).
Screening for colorectal cancer
According to the BRFSS in 1997, a total of 19.8% of
respondents age $ 50 years reported having under-
gone an FOBT during the preceding year, and 30.5% of
respondents reported having undergone a sigmoidos-
copy/proctoscopy within the past 5 years (Table 5).
More women than men reported having undergone
FOBT (21.0% vs. 18.4%). More men than women re-
ported having undergone sigmoidoscopy/proctoscopy
(35.2% vs. 26.8%). The proportions of AI/AN and API
who reported having undergone FOBT or sigmoidos-
copy/proctoscopy were lower than for whites or
blacks. A higher proportion of non-Hispanics than
Hispanics reported having undergone either test. The
overall proportion of respondents who reported hav-
ing undergone either test increased with age until age
70 –79 years, at which point it decreased with age
among older respondents. The proportion who re-
ported screening by either FOBT or sigmoidoscopy/
proctoscopy increased with increasing levels of edu-
cation and income and was higher among those
individuals who reported having health care coverage
compared with those who reported not having health
care coverage (data not shown and reference 23).
The state-specific proportion of respondents re-
porting undergoing FOBT during the preceding years
ranged from a high of 28.4% in Maine to a low of 9.2%
in Mississippi (Table 6). The proportion of respon-
dents reporting undergoing sigmoidoscopy/procto-
scopy during the preceding 5 years ranged from a high
of 41.5% in the District of Columbia to a low of 15.5%
in Oklahoma.
Data from the NHIS indicate that there were grad-
ual and modest increases in screening for colorectal
cancer over the period 1987–1998. In 1987 approxi-
mately 24% of individuals age $ 50 years reported ever
having undergone a proctoscopy/sigmoidoscopy ex-
FIGURE 6. Colorectal cancer incidence and death rates,a all races, both
genders, with joinpoint analyses for 1973–1997. a Incidence data are from 9
Surveillance, Epidemiology, and End Result (SEER) program areas covering
10% of U.S. population. Death data are from the National Center for Health
Statistics (NCHS) covering the entire U.S. population. Rates are per 100,000
persons and age-adjusted to the 1970 U.S. standard million population.
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amination.20 This proportion increased to 34% in 1992
and 38% in 1998. The proportion of individuals age $
50 years who reported undergoing FOBT within 2
years before the interview increased from 30% in 1992
to 33% in 1998. 20,21 The percentage of people age $ 50
years who reported undergoing FOBT within 1 year
increased from 15% in 1987 to 18% in 1992. NHIS rates
varied by income and education, with individuals with
less education or income less likely to be screened.25
DISCUSSION
Overall Cancer Incidence and Mortality Rates
Joinpoint analyses of cancer incidence and death rates
confirmed the declines reported previously.4,6 De-
creases in both incidence and death rates were noted
for the majority of the top ten cancer sites although
the rate of decline varied by tumor type, year of down-
turn, gender, and race. Incidence rates for all sites
combined increased slightly in the 1970s, increased at
FIGURE 7. Colorectal cancer inci-
dence and death ratesa by gender and
race, with joinpoint analyses for 1973–
1997. a Incidence data are from nine
Surveillance, Epidemiology, and End Re-
sults (SEER) program areas covering
10% of U.S. population. Death data are
from the National Center for Health Sta-
tistics (NCHS) covering the entire U.S.
population. Rates are per 100,000 per-
sons and age-adjusted to the 1970 U.S.
standard million population.
FIGURE 8. Colorectal cancer inci-
dence and death ratesa by gender and
race/ethnicity, 1990–1997. a Incidence
data are from 12 Surveillance, Epidemi-
ology, and End Results (SEER) program
areas covering 14% of U.S. population.
Death data are from the National Center
for Health Statistics (NCHS) covering en-
tire U.S. population. Rates are per
100,000 persons and age-adjusted to
the 1970 U.S. standard million popula-
tion. bAI/AN: American Indians/Alaska
Natives; bAPI: Asian/Pacific Islander.
c Hispanic is not mutually exclusive from
whites, blacks, American Indians/Alaska
Natives, and Asian and Pacific Islanders.
d Hispanic death rates exclude deaths
that occurred in Connecticut, Louisiana,
New Hampshire, and Oklahoma.
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a greater pace from 1983–1992, and then declined.
Death rates increased slightly over time through 1991,
at which time they reversed to a significant decrease,
with a more rapid decline between 1994 –1997. The
increased rate of decline in mortality after around
1994 occurred for all sites combined, specifically
among whites, all sites combined; prostate cancer
among white men; and breast cancer among white
women.
Greater than 50% of all cancer cases and cancer
deaths were caused by cancers of the breast, prostate,
lung and bronchus, and colon/rectum. The joinpoint
analysis of prostate cancer incidence rates identified
four trends: a steady increase from 1973–1988, an ac-
celeration in the increase from 1988 –1992, followed by
substantial decline from 1992–1995, and then approx-
imately level rates thereafter.
In 1995, the NCI reported a significant decline in
breast cancer mortality that began in 1989.26 Like nu-
merous other reports, the long term pattern of death
rates prior to this time was described as relatively
stable,26-28 even back to the 1930s.27 Several recent
reports found slightly increasing breast cancer death
rates averaging 0.2% per year (P , 0.05) from 1973–
1989.4,29,30 In addition to the decline beginning in
1989, the joinpoint analysis found breast cancer death
rates were level during the 1970s and then were in-
creasing on average 0.4% per year in the 1980s. This
more detailed look at the trends suggests that the
slightly increasing death rates previously reported for
the entire time period from 1973–19894,29,30 were con-
fined primarily to the 1980s.
Lung cancer mortality continues to increase signif-
icantly among women, although incidence rates in the
SEER population have leveled off. Joinpoint analyses of
trends in lung cancer incidence rates among women
identified four time periods with progressively slower
increases in rates, with the last interval (from 1991–1997)
being approximately level. In contrast, lung cancer death
rates among women increased throughout the study
period, although, similar to the trends in incidence rates,
the rates of increase progressively slowed. Further anal-
ysis of the trends in female lung cancer incidence rates
in other states is needed to determine whether the
differences between incidence and mortality rate
trends among women in this report reflect the well
known lag between changes in smoking behavior and
disease onset or death or whether the SEER areas have
been more successful in reducing tobacco use than the
U.S. at large.
The rates of prostate cancer incidence and male
lung cancer mortality are higher among blacks than
any other race or ethnic group. However, three can-
cers, those of the prostate, female breast, and male
lung, are the most common cancer incidence sites
among each of the racial/ethnic populations: white,
black, API, AI/AN, and Hispanic. With regard to mor-
tality, the most common cancer sites differ in that
female lung cancer eclipses female breast cancer for
white, black, API, and AI/AN populations, but not for
Hispanic women. Among Hispanic women, breast
cancer mortality is higher than lung cancer mortality.
These statistics suggest that greater efforts are needed
to address the disparities in cancer burdens among all
population subgroups in the U.S.
FIGURE 9. Colorectala cancer inci-
dence ratesb by anatomic subsite, gen-
der, and race, all ages, 1977–1997.
aColorectal excludes the large intestine,
not otherwise specified.b Incidence rates
are based on data from nine Surveil-
lance, Epidemiology, and End Results
(SEER) areas covering approximately
10% of the U.S. population. Rates are
per 100,000 persons and age-adjusted
to the 1970 U.S. standard million popu-
lation. Ascend: ascending.
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Colorectal Cancer Occurrence and Screening
Joinpoint analyses of trends in colorectal cancer inci-
dence rates showed increasing rates before the mid-
1980s followed by declines among whites and level
rates among blacks. Joinpoint analyses of trends in
colorectal cancer death rates identified one key
change in the long term decline: slightly decreasing
rates into the mid-1980s and then an acceleration in
the decline. This pattern was confined primarily to
whites.
A number of factors could contribute to the ob-
served decrease in the incidence rates. One study sug-
gested that the colorectal cancer incidence rate could
be reduced 66 –75% through diet and life-style
changes in the population.31 Such changes in diet32
(e.g., increases in intake of vegetables and other
sources of fiber and decreases in red meat intake and
alcohol) and increased physical activity33,34 may play a
role in the recent decline in incidence rates. Nondi-
etary factors such as changes in the levels of nonste-
roidal anti-inflammatory drugs consumed, including
aspirin,35 also may contribute to the declines. Re-
moval of adenomatous polyps detected through colo-
rectal cancer screening would also reduce the inci-
dence of cancer.36
Since the early 1970s, advances have been made
in treatment37 that seemingly would result in a re-
duced mortality rate. Surgical techniques, including
“no-touch” procedures, which were developed during
the 1970s and 1980s, lowered morbidity and mortality
TABLE 3
Colorectal Cancer Incidence Ratesa,b by Gender and Race, Selected States and Areas, 1993–1997
States and areas
Both genders Male Female
All races White Blackb All races White Blackb All races White Blackb
Arizona 36.9 37.3 37.1 43.9 44.3 43.6 31.2 31.5 31.9
California 40.5 40.4 47.8 48.4 48.2 54.5 34.2 34.1 42.5
Greater Bay Area 39.8 38.7 49.1 49.7 49.8 54.0 35.4 36.1 38.4
Los Angeles 41.7 42.1 45.3 48.1 47.0 55.4 33.5 32.4 44.4
Colorado 37.4 37.3 39.5 44.2 44.2 43.4 32.0 31.9 36.1
Connecticut 48.3 48.0 51.8 58.2 57.9 65.8 40.9 40.5 43.0
Delaware 48.2 47.6 50.6 57.9 57.6 59.2 40.7 39.7 44.5
Florida 47.8 47.5 47.7 57.0 56.8 53.6 40.5 39.9 43.3
Georgia: Atlanta Metro 43.6 40.5 54.0 51.1 48.4 61.4 38.3 34.8 49.6
Hawaii 44.5 48.9 55.2 59.0 35.2 38.9
Idaho 37.3 37.4 44.1 44.3 31.6 31.6
Illinois 46.7 45.8 52.1 55.6 54.8 60.7 40.1 39.1 46.2
Iowa 49.6 49.6 48.6 58.5 58.5 55.3 42.6 42.6 43.9
Kentucky 45.8 45.3 54.3 54.3 53.7 66.2 39.3 38.9 45.7
Louisiana 45.3 44.7 47.1 54.6 54.5 55.1 38.5 37.4 41.7
Michigan: Detroit Metro 46.3 45.0 51.1 56.8 56.7 57.2 38.7 36.5 46.5
Minnesota 43.2 42.9 44.2 51.0 50.5 57.7 36.9 36.7 32.9
Montana 39.6 37.4 46.1 43.7 34.3 32.3
Nebraska 45.8 45.6 45.6 55.9 55.5 52.4 38.1 37.9 41.1
New Hampshire 48.4 47.7 56.7 55.9 41.5 40.9
New Jersey 51.7 51.8 51.9 62.8 63.2 60.2 43.4 43.1 45.9
New Mexico 33.5 34.1 33.0 39.7 40.4 37.6 28.2 28.8 29.9
North Carolina 38.3 37.7 41.7 45.9 46.1 45.7 32.7 31.3 39.4
Rhode Island 51.9 52.4 47.0 62.1 62.8 54.9 44.7 45.0 41.0
Utah 32.4 32.3 37.8 37.8 27.7 27.7
Washington: Seattle-Puget Sound 41.6 41.5 49.9 49.2 49.0 64.7 35.5 35.4 37.1
West Virginia 45.2 44.7 55.4 51.7 51.1 69.5 40.4 40.1 46.5
Wisconsin 49.3 48.7 51.9 58.8 58.1 61.5 41.7 41.1 44.2
SEER programc 42.8 42.4 49.7 51.2 50.8 57.0 36.2 35.8 44.5
NAACCR combineda 44.2 43.8 48.5 52.7 52.4 55.8 37.5 37.1 43.3
SEER: Surveillance, Epidemiology, and End Results; NAACCR: North American Association of Central Cancer Registries.
a Incidence data are for 28 states and areas that meet the North American Association of Central Cancer Registries (NAACCR) standards of highest quality for 1993 to 1997 (Surveillance, Epidemiology, and End Results
(SEER) program metropolitan areas within included states are not duplicated in rates). These states/areas cover 49% of the U.S. population. Rates are per 100,000 persons and age-adjusted to the 1970 U.S. standard
million population.
b Rates are suppressed when incidence rate counts are fewer than 20 in 5-year period.
c Includes Greater Bay Area (California), Los Angeles (California), Atlanta Metro (Georgia), Connecticut, Hawaii, Iowa, Detroit Metro (Michigan), New Mexico, Utah, and Seattle-Puget Sound (Washington).
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TABLE 4
Colorectal Cancer Mortality Ratesa,b by Gender, Race, and State, 1993–1997
State
Both genders Male Female
All races White Blackb All races White Blackb All races White Blackb
Alabama 14.9 13.8 19.8 18.2 16.9 23.9 12.7 11.6 17.1
Alaska 17.6 16.0 20.2 19.8 15.2 12.5
Arizona 14.6 14.7 19.0 17.6 17.8 21.6 12.2 12.3 17.1
Arkansas 16.6 15.8 24.0 20.4 19.6 28.9 13.7 12.9 20.8
California 15.0 15.0 21.2 18.0 18.1 24.2 12.7 12.6 18.8
Colorado 14.4 14.4 17.9 17.2 17.2 21.1 12.2 12.2 14.8
Connecticut 16.7 16.6 18.1 20.7 20.7 22.2 13.7 13.6 15.2
Delaware 19.0 18.1 26.3 22.8 22.2 28.3 16.0 14.9 24.4
Washington, DC 19.9 13.2 23.2 24.1 15.1 29.1 17.1 11.7 19.5
Florida 16.1 15.8 21.4 19.5 19.2 24.2 13.4 13.0 19.4
Georgia 15.6 14.4 20.5 18.9 17.6 24.5 13.3 12.1 18.0
Hawaii 13.7 17.0 16.7 21.6 11.0 12.7
Idaho 13.8 13.9 17.0 17.1 11.4 11.4
Illinois 18.8 18.1 25.9 23.3 22.7 31.0 15.6 14.8 22.6
Indiana 18.5 18.0 28.0 22.3 21.8 32.4 15.7 15.1 25.1
Iowa 18.5 18.5 20.9 22.1 22.1 31.4 15.8 15.9
Kansas 16.2 16.1 22.7 20.0 19.7 27.3 13.4 13.3 19.4
Kentucky 19.1 18.7 25.8 23.5 23.1 31.7 15.9 15.6 21.7
Louisiana 18.5 17.2 23.0 22.8 21.0 29.2 15.4 14.3 18.7
Maine 19.3 19.3 22.9 22.9 16.7 16.8
Maryland 19.5 18.5 25.1 24.0 23.0 30.2 16.3 15.3 21.5
Massachusetts 19.1 19.1 22.3 23.7 23.6 27.7 15.9 15.9 18.1
Michigan 17.3 16.6 22.9 21.5 20.9 26.5 14.2 13.4 20.3
Minnesota 15.5 15.4 19.3 19.0 18.8 29.7 12.6 12.7
Mississippi 16.4 14.6 21.4 20.2 18.4 25.6 13.7 11.8 18.5
Missouri 17.9 17.3 25.2 21.8 21.2 30.9 15.0 14.5 21.3
Montana 15.9 15.8 19.8 19.6 12.7 12.7
Nebraska 18.1 18.0 24.5 23.3 23.2 33.0 14.2 14.1 19.9
Nevada 17.1 16.9 23.0 21.0 20.9 28.2 13.7 13.4 19.3
New Hampshire 19.3 19.3 21.6 21.6 17.3 17.3
New Jersey 20.0 19.8 23.8 24.8 24.9 28.2 16.5 16.2 20.8
New Mexico 14.3 14.5 17.6 17.4 17.8 11.7 11.8
New York 18.9 19.0 19.9 23.3 23.5 24.4 15.8 15.9 17.0
North Carolina 16.7 15.6 22.8 20.3 19.3 26.0 14.2 12.8 21.0
North Dakota 17.4 16.9 22.4 21.9 13.8 13.3
Ohio 18.9 18.5 24.1 23.5 23.0 29.9 15.7 15.3 19.9
Oklahoma 16.1 16.0 23.1 19.4 19.2 30.2 13.6 13.6 18.2
Oregon 15.4 15.3 19.4 18.3 18.3 12.9 12.9
Pennsylvania 19.4 19.1 24.8 23.9 23.5 31.2 16.2 15.9 20.8
Rhode Island 19.0 19.1 24.3 24.3 24.5 15.5 15.4 25.6
South Carolina 17.1 15.6 22.1 21.4 19.7 27.6 14.1 12.6 18.7
South Dakota 17.2 17.1 20.9 21.0 14.3 14.2
Tennessee 17.4 16.2 27.1 21.2 19.9 32.6 14.7 13.5 23.6
Texas 16.1 15.4 24.6 20.1 19.4 30.5 13.0 12.3 20.4
Utah 12.3 12.2 14.1 14.0 10.8 10.8
Vermont 18.4 18.5 21.4 21.5 16.2 16.2
Virginia 17.3 16.0 24.9 20.8 19.4 29.6 14.8 13.7 21.6
Washington 15.2 15.2 21.7 18.1 18.0 31.3 12.9 13.0 13.4
West Virginia 18.4 18.2 28.0 21.8 21.6 33.0 15.9 15.6 24.3
Wisconsin 16.6 16.5 18.3 20.6 20.5 22.2 13.6 13.5 15.4
Wyoming 16.5 16.4 18.1 18.1 15.2 15.1
U.S. 17.2 16.8 22.8 21.0 20.6 27.5 14.4 13.9 19.7
a Death data are from National Center for Health Statistics (NCHS) covering the entire U.S. population. Rates are per 100,000 persons and are age-adjusted to the 1970 U.S. standard million population.
b Rates are suppressed when death counts are fewer than 20 in 5-year period.
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for abdominoperineal resection. After a 1990 consen-
sus conference, adjuvant chemotherapy (5-fluoroura-
cil and levamisole) became more widely used (Harlan
L, personal communication). Colorectal cancer
screening also contributes to the decline in mortality
by detecting the disease at an earlier stage.
The incidence and mortality rates for colorectal
cancer varied somewhat across states. Composite
colorectal cancer incidence rates from SEER and
NAACCR were similar. In comparing rates across dif-
ferent geographic areas, it is important to consider
possible underlying reasons for the observed varia-
tions. Differences among the state rates may be attrib-
utable to factors such as demographic characteristics,
risk factor prevalence, and variations in cancer regis-
tration operations (e.g., case ascertainment, resolu-
tion of duplicate reports of cases, and identification of
multiple primary cancers). The demographic charac-
teristics could include age, urbanization, race, and
ethnicity. Risk factors may include diet,32 aspirin
use,35 physical activity,33,34 genetic factors,38,39 and
hormone replacement therapy in women.40 A recent
study examined U.S. geographic variations in colorec-
tal cancer incidence rates for the period 1991–1995 for
such factors as screening penetration, race, urbaniza-
tion, data quality of cancer registration operations,
and unadjusted variation in population age struc-
tures.41 Among the 36 states and areas, including
those in the SEER program, analyses of the percent of
the population age $ 50 years that also were age 65
years and older explained 12% of the variance in colo-
rectal cancer incidence rates in men and 26% of this
variance in women. Thus, although the rates used in
comparative analyses are age-adjusted, this adjust-
ment does not control for the variation of the age
distribution within the oldest age groups (i.e., the pop-
ulation age $ 85 years). States or areas with a greater
proportion of older persons within the oldest age
groups would be expected to have a higher incidence
rate based on age alone unless the finding is spurious
and caused by an unknown factor associated both
with the colorectal cancer incidence rate and age-
adjustment.
The extent to which screening programs are
adopted by the population or to which community
physicians apply state-of-the-art treatment protocols
also influences incidence, survival, and mortality. The
1997 BRFSS findings suggest that screening for colo-
rectal cancer varied by state and was fairly low. Cer-
tainly, when comparing mortality by geographic area
and population, state-to-state variations in the avail-
ability and accessibility of standard cancer treatments
must be considered, especially in light of differences
in the utilization of specific cancer treatments by age,
race, and geographic area.42-47 New research is needed
to further our understanding of these differences.
Colorectal cancer incidence and death rates
among black men and women were higher than
among persons of other racial and ethnic groups.
Moreover, the disparity between blacks and whites in
TABLE 5
U.S. Prevalencea of Fecal Occult Blood Tests and Sigmoidoscopy/Proctoscopy among Adults Age > 50 Years by Selected Characteristics, 1997
Fecal occult blood test during preceding year Sigmoidoscopy/proctoscopy during preceding 5 years
Total %
(SE)
Male %
(SE)
Female
% (SE)
Total %
(SE)
Male %
(SE)
Female
% (SE)
19.8 (0.3) 18.4 (0.4) 21.0 (0.4) 30.6 (0.3) 35.2 (0.5) 26.8 (0.4)
Race
White 20.1 (0.3) 18.8 (0.5) 21.2 (0.4) 31.0 (0.3) 35.7 (0.6) 27.3 (0.4)
Black 20.5 (1.1) 18.4 (1.8) 21.9 (1.4) 29.9 (1.2) 34.8 (2.1) 26.5 (1.4)
API 11.5 (1.9) 7.4 (1.8) 14.8 (3.1) 25.9 (3.6) 36.0 (5.9) 18.3 (4.2)
AI/AN 12.1 (2.2) 14.7 (3.8) 9.5 (2.2) 24.2 (3.4) 28.8 (5.0) 19.5 (4.7)
Ethnicity
Hispanic 11.8 (1.2) 10.3 (1.7) 13.0 (1.6) 26.8 (1.8) 28.8 (2.9) 25.0 (2.2)
Non-Hispanic 20.3 (0.3) 18.8 (0.4) 21.4 (0.4) 30.8 (0.3) 35.6 (0.5) 26.9 (0.4)
Age (yrs)
50–59 15.6 (0.4) 13.9 (0.6) 17.1 (0.6) 23.8 (0.5) 27.4 (0.8) 20.5 (0.6)
60–69 21.9 (0.5) 20.1 (0.8) 23.4 (0.7) 33.3 (0.6) 39.4 (1.0) 28.2 (0.7)
70–79 23.7 (0.6) 23.3 (1.0) 23.9 (0.7) 37.1 (0.7) 43.2 (1.1) 32.9 (0.8)
80–84 22.8 (1.3) 24.1 (2.3) 22.0 (1.5) 32.6 (1.4) 37.2 (2.5) 29.9 (1.6)
851 16.7 (1.2) 17.3 (2.3) 16.4 (1.3) 30.5 (1.5) 36.6 (2.9) 27.6 (1.7)
SE: standard error; API: Asian/Pacific Islander; AI/AN: American Indian/Alaska Native.
a Prevalence estimates are from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System. Estimates do not include Puerto Rico.
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TABLE 6
U.S. Prevalencea,b of Fecal Occult Blood Tests and Sigmoidoscopy/Proctoscopy among Adults Age > 50 Years by State, Gender, and Race, 1997
State
Fecal occult blood test during preceding year Sigmoidoscopy/proctoscopy during preceding 5 years
Total
(%)
Male
(%)
Female
(%)
White
(%)
Blackb
(%)
Total
(%)
Male
(%)
Female
(%)
White
(%)
Blackb
(%)
Alabama 14.3 15.2 13.6 13.2 18.6 29.6 35.9 24.9 28.1 36.4
Alaska 15.4 14.8 16.1 15.6 33.0 35.4 30.5 34.1
Arizona 16.9 19.7 14.6 16.3 31.3 35.4 28.1 32.1
Arkansas 13.4 13.9 12.9 14.5 22.9 25.6 20.8 24.6
California 16.4 13.3 19.0 17.7 35.4 40.1 31.7 37.5
Colorado 24.0 25.0 23.1 23.5 30.7 34.2 27.7 31.4
Connecticut 24.2 21.8 26.1 24.6 35.1 37.9 32.8 36.1
Delaware 22.5 24.1 21.2 23.1 20.7 37.1 42.9 32.3 38.1 29.8
DC 25.6 24.6 26.4 30.3 23.3 41.5 44.8 39.1 47.7 38.6
Florida 24.0 22.2 25.4 24.9 28.6 32.1 25.8 29.1 21.8
Georgia 14.8 14.1 15.3 15.7 38.5 43.7 34.4 39.5 36.4
Hawaii 21.6 18.4 24.7 18.3 39.7 45.9 34.1 37.7
Idaho 17.6 14.4 20.3 17.9 26.1 29.7 23.1 25.9
Illinois 14.4 14.4 14.4 13.3 29.2 35.4 24.7 30.2
Indiana 16.0 14.0 17.7 16.0 23.9 28.7 20.1 23.7
Iowa 18.6 17.4 19.5 18.3 27.9 33.3 23.8 28.1
Kansas 23.0 22.4 23.4 22.6 29.9 35.4 25.3 29.2
Kentucky 18.2 15.4 20.4 17.6 28.2 25.3 29.5 22.0 25.1 28.3
Louisiana 16.9 16.1 17.5 16.3 21.9 26.2 29.0 24.1 25.4 28.7
Maine 28.4 25.3 31.0 28.4 32.0 33.8 30.6 31.9
Maryland 25.1 24.6 25.5 25.1 24.4 25.8 34.2 18.9 23.9 33.9
Massachusetts 28.1 21.2 33.7 28.7 31.0 40.7 23.3 32.0
Michigan 22.4 19.6 24.7 23.1 34.6 36.8 32.7 35.2 31.4
Minnesota 21.9 20.7 22.9 22.2 39.7 44.9 35.2 39.9
Mississippi 9.2 6.1 11.7 9.0 25.7 25.6 25.8 26.4 24.8
Missouri 17.2 15.2 18.7 17.1 29.6 32.2 27.7 30.3
Montana 16.6 13.0 19.7 16.7 25.4 26.0 24.9 25.1
Nebraska 17.8 15.8 19.5 17.8 24.1 29.3 19.8 24.3
Nevada 10.7 13.6 8.1 11.4 29.1 39.4 20.1 28.7
New Hampshire 26.8 23.0 30.0 26.6 33.4 41.1 26.8 33.3
New Jersey 21.7 21.5 21.8 21.9 29.6 37.8 23.3 31.6
New Mexico 15.0 12.4 17.2 15.5 27.0 33.7 21.4 28.3
New York 24.8 25.3 24.4 23.0 42.0 31.7 38.8 26.4 31.2 37.4
North Carolina 27.2 23.1 30.6 28.4 21.2 30.8 34.4 28.0 30.2 35.9
North Dakota 14.7 10.8 18.1 14.3 30.2 33.6 27.3 30.3
Ohio 18.4 18.2 18.6 18.6 16.8 30.1 36.9 24.7 30.4 27.7
Oklahoma 10.9 9.2 12.2 10.8 15.5 13.8 17.0 15.7
Oregon 23.9 20.0 27.1 24.0 30.8 35.1 27.2 30.7
Pennsylvania 22.0 21.2 22.6 22.0 31.9 38.5 27.0 31.7 37.0
Puerto Rico 16.1 14.4 17.4 15.6 20.5 26.5 15.8 20.9
Rhode Island 21.1 18.3 23.3 21.4 32.7 37.3 29.2 33.2
South Carolina 15.5 13.5 17.0 16.9 21.2 25.0 18.2 22.1 18.5
South Dakota 15.0 13.6 16.1 15.1 27.9 34.5 22.6 27.8
Tennessee 15.9 12.7 18.5 16.5 26.5 26.9 26.1 26.8 23.1
Texas 19.6 20.6 18.7 21.2 27.5 29.9 25.4 28.9
Utah 14.7 14.1 15.3 14.9 30.2 38.0 23.6 30.4
Vermont 26.6 25.1 27.7 26.7 28.5 33.1 24.7 28.8
Virginia 19.8 18.2 21.2 19.9 18.9 33.5 37.2 30.5 34.1 31.1
Washington 24.4 19.7 28.5 24.4 31.1 35.0 27.8 31.3
West Virginia 11.9 11.4 12.3 11.9 24.8 28.0 22.2 24.4
Wisconsin 17.2 15.5 18.6 17.8 34.3 38.7 30.7 34.8
Wyoming 14.3 12.5 15.9 14.7 30.0 32.6 27.8 29.6
United Statesc 19.8 18.4 21.0 20.1 20.5 30.5 35.2 26.8 31.0 29.9
DC: District of Columbia.
a Prevalence estimates are from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System.
b Percentages are suppressed when numerator or denominator counts are fewer than 20.
c Estimates do not include Puerto Rico.
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colorectal cancer death rates may be increasing. In the
1970s and early 1980s, the differences in female colo-
rectal cancer rates between blacks and whites were
small; in the 1990s, the racial trends among women
increasingly diverged. Among men, the pattern of
trends in rates was similar although the rates were
more variable.
For the 1990s, comparisons of trends in colorectal
cancer rates across the five racial and ethnic groups
were complicated by large year-to-year variations. Ex-
cept for the white population, colorectal cancer inci-
dence and mortality rates for men in these popula-
tions showed greater variation than for women. The
decreasing trends in incidence rates for black and
white men in the 1990s appeared stronger than those
for men of other races or ethnicity. Similarly, the
downward trends in incidence rates for black and
white women appeared greater than for API and His-
panic women, with the trend among AI/AN women
having the largest annual fluctuations.
Cancer rates vary considerably among AI48 and
AN populations.49 Colon cancer incidence rates in AN
men and women have increased significantly since the
early 1970s, and cancer of the colon/rectum was the
most frequently diagnosed malignancy in this popu-
lation between 1989 –1993, which is approximately 1.5
times higher than overall SEER incidence rates be-
tween 1989 –1992.50 Reasons for the higher rates of
colorectal cancer incidence among ANs are unclear.
The decline in colorectal cancer mortality in the
1990s was evident among men of all racial groups
except among AI/AN, in whom the annual fluctuation
in rates made the interpretation of trends less clear.
Although these recent trends are encouraging, contin-
ued improvement for all racial/ethnic groups is
needed.
Limitations of Cancer Occurrence and Screening Data
It is difficult to use one summary statistic to describe
long-term cancer trends. Therefore, two approaches
were used to study trends. First, incidence and mor-
tality trends were compared by site and gender for the
same recent time period (1990 –1997). In addition, the
new joinpoint method provided a more detailed de-
scription of the cancer pattern over the 25-year period.
For many malignancies, incidence and death rates
have shown recent declines after increasing during
earlier time periods.
For the first type of analyses, the APC statistic was
used to describe short-term trends in the 1990s. The
underlying assumption was that the rates increased or
decreased at a constant rate over the time interval
(1990 –1997). Trends based on 1990 –1997 data may be
compared across cancer sites, genders, racial and eth-
nic populations, and other groups as necessary. For
the second type of analysis, the joinpoint method
allowed more flexible, and perhaps more accurate,
analyses so that the year(s) are identified in which
significant changes in the trends occurred. This
method was adopted to describe better the cancer
patterns over long periods of time in contrast to iden-
tifying only one trend statistic as was done in previous
reports. The joinpoint analysis for each site, race, and
gender showed different cancer incidence and death
patterns. Because the rates for blacks are based on
fewer cases than those for whites, the rates for blacks
have more variation. Thus, the joinpoint analysis may
not be as able to discern changes in trends among
blacks compared with whites. For example, the colo-
rectal cancer incidence rates for black men appear as
though they may have begun to decline. However, the
joinpoint analysis cannot detect this as yet due to the
variability in the rates for black men (Fig. 7). If the
trends are not linear, the APC will lack statistical sig-
nificance. In addition, some random variation exists in
rates across the years. Although the joinpoint analysis
provides a precise description of trends for persons of
a particular race and gender, comparisons across dif-
ferent races and genders may be more difficult be-
cause each may have a different number of joinpoints
and may have different years of inflection.
Assessments of the absolute and comparative lev-
els of cancer incidence and death rates by race and
ethnicity need to be tempered by the recognition of
potential biases in the data. The biases may result
from misreporting race and ethnicity and, to a lesser
extent, age on the basic records from which informa-
tion is collected with regard to cancer incidence death,
and the population at risk.51-55 Rates may be biased
because of misreporting on death certificates
(NCHS)51–53 and hospital medical records,54 which
comprise the numerators of the cancer death and
incidence rates, respectively, and on censuses and
surveys, which comprise the denominators of the
rates. Recent evaluation studies suggest that the re-
porting of race for the white and black populations
generally is reliable, and that biases are more serious
for some of the smaller populations, particularly for
American Indians.52,54 Although these biases affect
comparisons among groups at a specified point in
time, the trend data for both incidence and death rates
are considered to be relatively reliable.
Survival rates have several limitations. First, al-
though they provide some indication of the average
survival experience of cancer patients in the U.S., they
are less useful in predicting survival for individual
cancer patients. Second, they are based on cases that
were diagnosed as many as 8 years previously and
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therefore cannot reflect the most recent advances in
screening and treatment.56
The receipt of cancer screening tests is self-re-
ported by NHIS and BRFSS survey respondents and
not validated; in addition, the two surveys have differ-
ent response rates and use different wording for the
questions.57 One limitation of these data is that re-
spondents may not comprehend fully the descriptions
of medical procedures from a survey question, may
not remember receiving a screening procedure, or
may not accurately estimate how much time has
elapsed from the receipt of the procedure to the time
of the survey. Efforts have been made in recent years
to improve the detail, validity, and comprehensibility
of NHIS questions regarding colorectal cancer screen-
ing procedures. The BRFSS is subject to the additional
limitation that it is a telephone survey, and only per-
sons with a telephone were represented. However,
95% of Americans now have telephones although this
varies by population group.57 The BRFSS question-
naire also did not distinguish between tests conducted
for screening as opposed to those conducted for diag-
nostic purposes. Therefore, the actual prevalence of
these tests for screening purposes most likely is lower
than reported by the BRFSS.
Strategies for the Future
Colorectal cancer screening was not responsible for
the early declines in colorectal cancer death rates be-
cause colorectal cancer death rates, especially for fe-
males, have been declining since the 1950s, which was
prior to the publication of screening guidelines. How-
ever, screening may have played a role in the more
recent, steeper declines in colorectal cancer incidence
and death rates and has the potential for increased
benefits in the future. The U.S. Preventive Services
Task Force,58 the American Cancer Society,59 and the
Interdisciplinary Task Force60 have established new
screening guidelines for colorectal screening. These
guidelines, published in the mid-1990s, emphasize the
benefits of early detection and treatment of precan-
cerous polyps and cancer through the use of FOBT,
sigmoidoscopy, colonoscopy, and barium enema.
Despite the guidelines, NHIS and BRFSS show
low levels of FOBT and sigmoidoscopy/proctoscopy
within the recommended time periods. However,
the NHIS survey shows small increases in preva-
lence from 1987–1998. For screening to be effective
in reducing morbidity and mortality from colorectal
cancer, it must be performed on a regular basis (i.e.,
in compliance with recommended guidelines); how-
ever, the prevalence of repeat screening has been
reported to be low for both FOBT and sigmoidos-
copy.61 Recent reviews of the literature regarding
patient and provider adherence to colorectal cancer
screening guidelines point to the need to address
barriers.61,62 Surveys of patients showed that for
both FOBT and sigmoidoscopy, practical concerns
(e.g., conflicts with work or family, inconvenience,
being too busy, cost) and not currently having
symptoms or health problems were the most impor-
tant reasons for not taking an opportunity to be
screened.61 Provider barriers to offering FOBT in-
cluded forgetfulness, perceived ineffectiveness,
cost, and inconvenience to patients.62 Reasons pro-
viders gave for not offering sigmoidoscopy included
patient discomfort, provider inconvenience, lack of
time, low probability of finding a lesion, lack of
experience or training in sigmoidoscopy, and cost.
Based on our knowledge, interventions to increase
patient and provider adoption of colorectal cancer
screening have met with only modest success.61,62
There are a number of ongoing NCI-funded studies
of behavioral interventions to increase rates of colo-
rectal cancer screening in both patient and provid-
ers. The ACS, NCI, and CDC are in the process of
conducting national provider and patient surveys
regarding colorectal screening practices in health
care organizations. One survey currently is being
administered to primary care physicians, specialists
and patients to assess their knowledge, attitudes,
and practices related to colorectal screening.63 An-
other survey is directed toward health plan medical
directors with a focus on coverage policies, guide-
lines, and programs for colorectal cancer screening.
Data from these studies should be useful in devel-
oping and refining strategies to overcome patient
and provider barriers.
Public education efforts currently are being di-
rected toward increasing awareness of the benefits of
colorectal cancer screening. Activities include the Na-
tional Colorectal Cancer Roundtable, established by
the CDC and ACS to strengthen the network of private
and public organizations, including the NCI, promot-
ing colorectal cancer screening. In March 1999, a na-
tional education campaign called “Screen for Life: Na-
tional Colorectal Cancer Action Campaign” (available
at URL: www.cdc.gov/cancer/ScreenForLife) was
launched to inform men and women age $ 50 years
about the importance of colorectal cancer screening
for early detection and prevention. The CDC has
spearheaded this effort in collaboration with the
Health Care Finance Administration (HCFA) and the
NCI. The CDC and NCI also are working with the
HCFA to promote Medicare’s new coverage for colo-
rectal cancer screening. In the U.S., March has been
established as “National Colorectal Cancer Awareness
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Month” to focus more attention and efforts toward the
prevention and early detection of colorectal cancer.
Cancer incidence and death rates were reported
separately for white, black, API, AI/AN, and His-
panic populations. These broad groupings of race
and ethnicity for cancer incidence and death rates
may be obscuring important differences in more
specific populations such as Chinese-Americans
and Japanese-Americans, 64 Hispanics from differ-
ent nationalities and cultures,65 rural populations,
populations of low socioeconomic status or low educa-
tional levels,66 or those with limited access to medical
care. Methods to study incidence and death rates by
urban-rural designation and socioeconomic indicators
at the individual and social-structural level currently are
in progress. If determined to be reliable and meaningful,
they can be applied to the data regarding U.S. cancer
incidence and mortality.
Measuring the occurrence of cancer by race/eth-
nicity and other sociodemographic characteristics
serves to identify subgroups of the population who are
at increased or decreased risk. To our knowledge, data
concerning adherence to colorectal cancer screening,
diagnostic evaluation, and treatment modalities by
race/ethnicity and other demographic factors are
sparse, but the literature suggests other areas of can-
cer prevention and control in which special efforts will
be needed to ensure the participation of medically
underserved populations in the continuum of care for
colorectal cancer. Developing strategies to encourage
the adoption of effective prevention, screening, diag-
nostic evaluation, and treatment modalities, requires
understanding cultural differences in literacy, lan-
guage, world view, beliefs, values, social norms, help-
seeking behaviors, and attitudes toward and access to
medical care. Cultural factors and other important
determinants must be incorporated into interven-
tions, and ultimately into standard medical practice,
so that the benefits of state-of-the-art knowledge and
practice will be realized by all.
In the future, expanded study of special popula-
tions such as AI/AN, Hispanics of different national
origins, populations in the southeastern U.S., Appala-
chia, rural America, and other geographic locations
should be possible as the number of population-based
cancer registries, with high quality cancer incidence
data, increases as a result of the expansion of the SEER
program and renewal of the CDC’s National Program
of Cancer Registries (NPCR). The NAACCR has estab-
lished criteria and standards to assess the quality of
registry data. These should be expanded to include an
evaluation of the accuracy and reliability of case
counts and population data for racial and ethnic
groups other than blacks and whites before these data
can be utilized fully. To begin this, several NAACCR
workgroups have been formed to address the quality
of the race/ethnic data with the initial focus in 2000 on
the reliability of identifying AI/AN, API, and Hispanic
populations across all U.S. registries.
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